Oncomine Dx (CDx) for Non–Small Cell Lung Cancer (NSCLC) Treatment Monitoring
The Oncomine Dx Target Test is an in vitro diagnostic, next-generation sequencing test designed to detect somatic alterations in DNA and RNA isolated from non-small cell lung cancer (NSCLC). This test mainly detects single-nucleotide variants (SNVs) and deletions in 23 genes from DNA and fusions in ROS1 from RNA isolated from formalin fixed paraffin embedded (FFPE) tumor tissue samples. Target genes include: AKT1, ALK, BRAF, CDK4, DDR2, EGFR, ERBB2, ERBB3, FGFR2, FGFR3, HRAS, KIT, KRAS, MAP2K1 (aka MEK1), MAP2K2 (aka MEK2), MET, MTOR, NRAS, PDGFRA, PIK3CA, RAF1, RET, and ROS1. This test is an FDA-approved companion diagnostic indicated as an aid for selecting NSCLC patients for three targeted therapies:
- Tafinlar® in combination with Mekinist® (dabrafenib/trametinib) in the presence of BRAF V600E mutation
- Xalkori® (crizotinib) with ROS1 fusions; and
- Iressa® (gefitinib) with EGFR L858R mutation or exon 19 deletions.
- To help identify patients with EGFR Exon20 insertion mutation-positive in metastatic non-small cell lung cancer (mNSCLC) as candidates for EXKIVITY(mobocertinib) treatment
- As an aid in selecting NSCLC patients for treatment with XALKORI® (crizotinib)
- As an aid in selecting NSCLC patients for treatment with Tafinlar
- Mekinist® (dabrafenib in combination with trametinib)
- As an aid in selecting NSCLC patients for treatment with IRESSA® (gefitinib)
- As an aid in selecting NSCLC patients for treatment with Gavreto® (pralcetinib)
- Positive: BRAF V600E, associated therapy- Tafinlar+ Mekinist® (dabrafenib in combination with trametinib)
- Positive: ROS1 fusion, associated therapy- XALKORI® (crizotinib)
- Positive: RET fusion, associated therapy- Gavreto® (pralcetinib)
- Positive: EGFR L858R– and Exon 19 deletion (associated therapy- IRESSA® (gefitinib)
No pathogenic variants (mutations) detected
Formalin fixed paraffin embedded (FFPE) tissue samples.
Stability
FFPE samples are stable at room temperature for longer.
- JMA J. 2024 Jul 16;7(3):375-386. [PMID: 39114611]
- Genes (Basel). 2023 Jun 2;14(6):1219. [PMID: 37372399]
- Clin Lung Cancer. 2019; 20: 20-29.e8. [PMID: 30243889]
- Cancers (Basel). 2019;11. pii: E1309. [PMID: 31491926]
- Adv Exp Med Biol. 2016; 893: 1-19. [PMID: 26667336]
- N Engl J Med. 2014 Nov 20;371(21):1963-71. [PMID: 25264305]
- Thorac Cancer. 2021 Feb;12(4):504-511. [PMID: 33350072]
- Oncomine® Dx Target Test User Guide, Rev C.0, 2017
- Thermo Fisher Scientific: Oncomine Dx Express Test